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Abstract 
 As reflected in the 2005 USEPA Guidelines for Cancer Risk Assessment, some chemical 
carcinogens may have a site-specific mode of action (MOA) that is dual, involving mutation in 
addition to cell-killing induced hyperplasia.  Although genotoxicity may contribute to increased 
risk at all doses, the Guidelines imply that for dual MOA (DMOA) carcinogens, judgment be 
used to compare and assess results obtained using separate “linear” (genotoxic) vs. “nonlinear” 
(nongenotoxic) approaches to low-level risk extrapolation.  However, the Guidelines allow the 
latter approach to be used only when evidence is sufficient to parameterize a biologically based 
model that reliably extrapolates risk to low levels of concern.  The Guidelines thus effectively 
prevent MOA uncertainty from being characterized and addressed when data are insufficient to 
parameterize such a model, but otherwise clearly support a DMOA.  A bounding factor 
approach—similar to that used in reference dose procedures for classic toxicity endpoints— can 
address MOA uncertainty in a way that avoids explicit modeling of low-dose risk as a function 
of administered or internal dose.  Even when a “nonlinear” toxicokinetic model cannot be fully 
validated, implications of DMOA uncertainty on low-dose risk may be bounded with reasonable 
confidence when target tumor types happen to be extremely rare.  This concept was illustrated 
for the rodent carcinogen naphthalene.  Bioassay data, supplemental toxicokinetic data, and 
related physiologically based pharmacokinetic and 2-stage stochastic carcinogenesis modeling 
results all clearly indicate that naphthalene is a DMOA carcinogen.  Plausibility bounds on rat-
tumor-type specific DMOA-related uncertainty were obtained using a 2-stage model adapted to 
reflect the empirical link between genotoxic and cytotoxic effects of the most potent identified 
genotoxic naphthalene metabolites, 1,2- and 1,4-naphthoquinone.  Resulting bounds each 
provided the basis for a corresponding “uncertainty” factor <1 appropriate to apply to estimates 
of naphthalene risk obtained by linear extrapolation under a default genotoxic MOA assumption.  
This procedure is proposed as scientifically credible method to address MOA uncertainty for 
DMOA carcinogens. 
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Introduction  
 Current multistage cancer theory and the Guidelines for Cancer Risk Assessment 
(USEPA, 2005) recognize that a chemical carcinogen may have a site-specific mode of action 
(MOA) that is dual, involving mutation in addition to cell-killing induced hyperplasia, and that in 
such a case the relative contributions of each mode to increased risk may change as a function of 
dose.  In contrast, the Guidelines suggest that “linear” vs. “nonlinear” approaches to risk 
extrapolation are dichotomous, and they vaguely recommend that in ambiguous cases, judgment 
should be used to compare and assess results obtained using “both” of these two approaches (see 
Appendix).  Notably, the Guidelines are unclear about exactly how MOA uncertainty should be 
characterized and addressed in the case that bioassay and supplemental mechanistic toxicokinetic 
data for a given tumor site 
 
• clearly support a dual MOA (DMOA),  
• establish with reasonable certainty that the default “linear” extrapolation procedure 
is not scientifically plausible (without at least some modification to reflect the 
nongenotoxic MOA exhibited by the data), but are nevertheless 
• insufficient to parameterize a biologically based model that reliably extrapolates 
human (or bioassay animal) risk to very low, environmentally relevant levels of 
exposure. 
 
This generic case is problematic because the Guidelines recommend that this “ambiguous,” 
DMOA case be addressed only by either (or both) of two quite different dose-response 
extrapolation procedures:  linear extrapolation for “genotoxic” carcinogens, and traditional 
nonlinear uncertainty-factor methodology for “nongenotoxic” carcinogens.  Specifically, the 
Guidelines recommend that “If there are multiple modes of action at a single tumor site, one 
linear and another nonlinear, then both approaches are used to decouple and consider the 
respective contributions of each mode of action in different dose ranges” (see Appendix).  The 
“catch-22” is that elsewhere the Guidelines allow this recommendation to be pursued for a 
nongenotoxic carcinogen only when available data either (a) clearly demonstrate that an 
exclusively nongenotoxic MOA is applicable, or (b) establish and validate a comprehensive 
toxicokinetic model applicable to the carcinogen in question.  Option (a) is by definition 
inapplicable to any DMOA carcinogen, and a comprehensive toxicokinetic model to pursue 
option (b) has not yet been accepted for regulatory application to any carcinogen (with a DMOA, 
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or any other MOA).  To pursue option (b), must a biologically based a toxicokinetic model be 
validated for application at all dose levels before any consideration may be given to any of its 
logical implications that are based on convincing mechanistic data? 
 For example, suppose histological evidence from a positive chemical carcinogen bioassay 
indicated unambiguously that dose-related cell-killing had induced regenerative hyperplasia at 
multiple sites of tumorigenesis in cells histologically related to, and plausibly precursors of, 
dose-related tumors of types i each observed to occur at a rate Ri significantly elevated above its 
corresponding background tumor rate (ri).  Further assume that no tumor types were significantly 
elevated other than those also associated in each case with histologically related hyperplasia, that 
the chemical is known from in vitro and in vivo studies to be cytotoxic particularly to cells of 
types that occur at only sites of observed dose-related tumorigenesis, and that species- and site-
specific cytotoxicity of the compound is predicted by detailed and validated physiologically 
based pharmacokinetic (PBPK) modeling.  Based on current mechanistic-multistage cancer 
theory (e.g., Moolgavkar, 1983; Bogen, 1989), the observed dose-induced, histologically linked 
hyperplasia would almost certainly have contributed to amplification of Ri, albeit by unknown 
relative site-specific factors Fh, where Fh ≤ Ri /ri.  Absent evidence of genotoxicity by the test 
chemical or any of its metabolites, it could be argued that this chemical has a nongenotoxic 
MOA with Fh = Ri /ri.  Now we add a final assumption that the chemical involved and/or its 
metabolite(s) is known to be genotoxic.  Even with this final assumption, it still would be 
scientifically implausible to claim Fh = 1, given the assumed histological and mechanistic 
evidence.  While the evidence that Fh > 1 is convincing in this hypothetical case, the magnitude 
by which Fh is >1 remains uncertain.   A biologically based 2-stage “cell kinetic” 
(toxicodynamic) cancer model could in this case realistically reflect the high likelihood that both 
genotoxic and hyperplastic (nongenotoxic) MOAs acted jointly to produce the observed response 
(Moolgavkar, 1983; Bogen, 1989).  Even so, the Guidelines supply no clear method to quantify 
the impact of Fh and its uncertainty on extrapolated risk.  They instead recommend that “An 
analysis of model uncertainty can be used to determine the range where extrapolation using the 
toxicodynamic model is supported and where further extrapolation would be based on either a 
linear or a nonlinear default, as appropriate” (see Appendix).  This recommendation begs the 
question of how to avoid the “catch-22” problem described above. That is, in this case must the 
means by which uncertainty is addressed be limited only to a characterization of uncertainty 
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potentially associated with the genotoxic MOA default, to be “explored” providing illustrative 
and admittedly irrelevant results of a nonlinear, “reference dose” extrapolation procedure applied 
to a toxicokinetic model assuming a nongenotoxic MOA—i.e., contrary to the evidence of an 
operative genotoxic MOA that is presumed in this hypothetical example? 
 While the Guidelines for Carcinogen Risk Assessment offer no clear solution to this 
dilemma, there is ample precedent to address it reasonably and explicitly using standard 
procedures from the USEPA “reference dose” process (USEPA, 2002), when available evidence 
so warrants.  In the hypothetical case above, for example, such an approach might be warranted 
in the special circumstance that all relevant background tumor rates are extremely small (e.g., 
<10-3).  In this circumstance, despite the fact that available toxicokinetic data might be 
insufficient to fully validate a toxicokinetic model applicable to environmental levels of risk 
extrapolation, those data could be sufficient to conclude with reasonable certainty that linear risk 
extrapolation assuming a fully genotoxic MOA from a “point of departure” derived from 
bioassay data will substantially overestimate true incremental risk at very low doses.  One 
context in which such reasonable certainty can arise is proposed here, namely, when:  
 
(I) histological evidence confirms that observed tumor response rates at all dose levels of 
each positive bioassay have almost certainly been augmented by dose-related, 
histologically associated (e.g., cell-killing induced regenerative) hyperplasia, and  
 
(II) supplemental toxicokinetic data establish that any dose-related genotoxicity is 
invariably accompanied by similar hyperplasia reasonably expected to amplify any 
purely genotoxic tumor risk, according to a biologically based multistage (e.g., MVK) 
model parameterized in a way constrained to reflect the maximum genotoxic tumor 
risk that is plausible conditional on all relevant data. 
 
If conditions I and II hold in this hypothetical case, it should be possible to estimate from the 
constrained MVK model the minimum plausible factor, Min(Fh), by which linear genotoxic 
extrapolation overestimates the true low-dose cancer risk that is consistent with the available 
data. 
 Along these lines, it is proposed that low-dose risk implications of DMOA uncertainty 
can be addressed using mechanistic toxicokinetic models that incorporate physiologically based 
pharmacokinetic (PBPK) and 2-stage stochastic carcinogenesis (MVK) model components, 
which in turn are sufficiently general to reflect a DMOA assumption.  Data are not likely to 
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become .  Specifically, in the special case when all relevant target tumor types happen to be 
extremely rare, it is proposed that evidence may be sufficient to characterize and address DMOA 
uncertainty in particular, and its low-dose implications for risk extrapolation, with reasonable 
confidence based on mechanistic modeling.  An implementation of these propositions is here 
illustrated for the carcinogen naphthalene, which EPA recently proposed to reclassify based on 
NTP bioassay data indicating increased risk of very rare nasal tumors in rats, in addition to 
earlier NTP and other data indicating increased risk of lung tumors in mice (USEPA, 1998, 
2004).  Bioassay and in vitro data together with PBPK modeling results are shown to indicate 
with high confidence that naphthalene is a DMOA carcinogen.  Plausibility bounds on rat-tumor-
type specific DMOA-related uncertainty are then obtained using an MVK model reflecting in 
vitro data that links genotoxic and cytotoxic action of the most potent identified genotoxic 
naphthalene metabolites, 1,2- and 1,4-naphthoquinone.  The resulting bounds are finally used to 
provide the basis for corresponding “uncertainty” factors <1 appropriate to apply to estimates of 
naphthalene risk obtained by linear extrapolation under a default genotoxic MOA assumption, to 
illustrate the proposed scientifically credible method to address MOA uncertainty for DMOA 
carcinogens. 
 The following analysis first briefly summarizes key data concerning the ability of 
naphthalene to induce cancer in rodents; concerning naphthalene metabolism and related 
cytotoxicity; and concerning genotoxicity of naphthalene and its metabolites, and its relation to 
associated cytotoxicity.  Recently developed PBPK models for naphthalene are then used to 
assess a mechanistic basis for site- and species-specific target-organ cytotoxicity.  MVK 
modeling results are next presented that incorporate in vitro data relating naphthalene mutagenic 
to cytotoxic potency.  To illustrate the proposed scientifically credible method to address MOA 
uncertainty for a DMOA carcinogen like naphthalene, these MVK modeling results are finally 
used to obtain corresponding “uncertainty” factors <1 appropriate to apply to estimates of 
naphthalene risk based on linear extrapolation under a default genotoxic MOA assumption. 
 All calculations reported below were performed using Mathematica 5.0® software 
(Wolfram, 1999), using methods described below. 
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Naphthalene Carcinogenicity 
 Case reports of cancer in naphthalene-exposed humans involve four laryngeal cancer 
cases among smokers in workers at an East German naphthalene purification plant (Kup, 1978; 
Wolf, 1976, 1978), and a series of 11 colorectal carcinoma patients 18 to 30 years old admitted 
to a Nigerian hospital, “half” of whom “gave a definitive history of ingesting” the “naphthalene 
compound” kafura used as part of “local indigenous treatment for ‘piles’ or any anorectal 
problem” (Ajao et al., 1988).  These case reports have been considered insufficient to evaluate 
human carcinogenicity of naphthalene (USEPA, 1998, 2004; IARC, 2002).  Incidences of 
alveolar/bronchiolar adenomas or carcinoma were increased in female (but not male) B6C3F1 
mice exposed to 30 (but not to 10) ppm naphthalene for 2 years (NTP, 1992; Abdo et al., 1992).  
A previous study found increased tumor multiplicity in tumor-bearing A/J strain mice exposed to 
10 or 30 ppm for 6 months (Adkins et al., 1986).  More recently, increased incidences of rare 
respiratory epithelial adenomas and of rare olfactory epithelial neuroblastomas were observed in 
female rats, and rare respiratory epithelial adenomas were observed in male rats, exposed to 
naphthalene vapor concentrations of 10, 30, or 60 ppm for 2 years (NTP, 2000; Abdo et al., 
2001; Long et al., 2003). 
 The U.S. Environmental Protection Agency (EPA) classified naphthalene as a possible 
human carcinogen (Group C, inadequate human and limited animal data), concluding that its 
human carcinogenic potential could not be determined from available suggestive rodent tumor 
data, and that “it appears unlikely that naphthalene represents a genotoxic carcinogen” (USEPA, 
1998).  The International Agency for Cancer Research (IARC) classified naphthalene as a 2B 
carcinogen (possibly carcinogenic to humans) based on the inhalation bioassay data in animals 
noted above (IARC, 2002).  The EPA subsequently proposed to reclassify potential human 
carcinogenicity of naphthalene from “possible” to “likely” and has developed corresponding 
linear no-threshold risk extrapolations (USEPA, 2004).  The latter proposal presumed, in 
accordance with default carcinogen risk assessment guidelines (USEPA, 2005), that combined 
data from lifetime bioassays of cancer induced in B6C3F1 mice and F344/N rats exposed 
chronically to naphthalene by inhalation (NTP, 1992, 2000) are plausibly consistent with an 
exclusively or predominantly genotoxic MOA.  Current bioassay data thus clearly establish that 
chronic inhalation of naphthalene can induce respiratory tract tumors in rodents.  However, 
classification of naphthalene “carcinogenicity” per se begs the question concerning the nature of 
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low-dose dose-response for naphthalene-induced cancer risk either to humans or to rodents. 
 Alveolar/bronchiolar adenomas (and one carcinoma) were significantly increased by 
chronic inhalation of 30 ppm (but not 10 ppm) naphthalene by female B6C3F1 mice; relatively 
high mortality in control male mice in this study made results in that sex more difficult to 
evaluate (NTP, 1992, 2002; Abdo et al., 1992).  Histopathology findings from this study are 
consistent with DMOA carcinogenesis, particularly in view of related cytotoxicity information 
from other studies.  Chronic naphthalene exposures at these levels produced dose-dependent 
cytotoxicity in the same (distal-bronchial/alveolar) lung region in mice, but not in rats (West et 
al., 2001).  Relative to neighboring cells, non-ciliated Clara cells exhibited particularly high 
susceptibility to naphthalene-induced cytotoxicity.  These cells also demonstrate the greatest 
capacity to metabolize naphthalene, as discussed below.  General, granulomatous and glandular 
inflammation and alveolar epithelial hyperplasia were all significantly elevated among the high-
dose female mice.  “Alveolar epithelial hyperplasia occurred primarily in or adjacent to areas of 
inflammation” (Abdo et al., 1992).  In earlier studies, a single 125- or 250-mg/kg ip injection of 
naphthalene was sufficient to cause bronchial and bronchiolar epithelial necrosis in mice (Mahvi 
et al., 1977, Tong et al., 1981).  Mild to moderate nasal respiratory epithelial hyperplasia also 
occurred in 100% of all dosed female and in >95% of all dosed male mice, but in virtually none 
of the control mice.   
 Histopathology findings obtained from the NTP (2000) rat bioassay provide clear 
evidence that nasal tumor formation in rats chronically exposed to naphthalene by inhalation was 
at least substantially influenced, if not driven primarily, by chronic tissue damage and associated 
regenerative and focal hyperplasia.  The extent of chronic nasal cytotoxicity and hyperplasia 
detected in nearly 100% of all exposed animals (regardless of dose group) was described by 
Long et al. (2003) as follows (bold added): 
 
“Neuroblastomas occurred amid a complex spectrum of nonneoplastic lesions of 
the olfactory epithelium.  The principal nonneoplastic proliferative lesion was 
atypical hyperplasia, which … consisted of proliferating nests of dysplastic olfactory 
epithelial cells … and/or multifocal nodular proliferations of basal cells extending 
into the submucosa …. The hyperplastic cells were deeply basophilic and, in many 
areas, continuous with the neoplasms.  Such continuity was most clearly observed 
in association with small neuroblastomas.  Atrophy of olfactory epithelium was 
characterized by … loss of epithelial cells … there was also loss of olfactory neurons.  
The most severe lesions had complete loss of sustentacular cells and neurons, leaving 
only basal epithelial cells. 
 
Respiratory epithelial adenomas also occurred amid a spectrum of non-neoplastic 
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lesions of the respiratory epithelium and the submucosal glandular epithelium. … In a 
few animals, focal proliferation of hyperplastic cuboidal respiratory epithelium 
resembled early adenoma formation.  
 
… Although the incidence and severity of these non-neoplastic lesions frequently 
increase in an exposure-dependent manner, they commonly occur with no evidence 
of nasal carcinogenicity, indicating that factors other than the extent of tissue injury 
from chronic nasal toxicity contribute to nasal carcinogenesis … .  Atypical 
hyperplasia of the olfactory basal cells occurred at very high frequencies in all male 
and female groups exposed to naphthalene.  This was considered an unusual 
proliferative lesion, because it had not been reported in previous NTP inhalation 
studies.  Morphologically, these cells were similar to, and frequently formed a 
continuum with, those of the neuroblastomas. This appearance suggests that the 
atypical hyperplasia may represent a precursor for nasal olfactory carcinogenesis.  
In addition, a few animals had localized proliferative changes of the respiratory 
epithelium that were morphologically similar to respiratory epithelial adenomas. ” 
 
This description of cytotoxicity and hyperplasia, in direct association with the observed nasal 
neuroblastomas and nasal respiratory epithelial adenomas, is similar to descriptions of multistep 
neoplastic transformation from focal hyperplastic tissue to nodular hyperplasia to adenomas or 
carcinomas observed in chemically induced or promoted carcinogenesis in the rodent liver and 
gastrointestinal tract (Farber, 1984; Farber and Cameron, 1984; Pitot et al., 2000).  While 
initiation with a genotoxic agent is typically used in these experimental rodent carcinogenesis 
systems in order to generate observable tumor rates, subsequent promotion involving either 
enhanced cell proliferation, or just oxidative stress associated with additional genotoxic or 
cytotoxic exposure(s) (Sanchez-Perez et al., 2005), can be required to elevate these rates to 
observable levels. 
 Naphthalene was clearly cytotoxic to epithelial and neural cells in nasal tissue of exposed 
NTP (2000) bioassay rats.  The observed cytotoxic damage and histologically linked 
regenerative hyperplasia strongly support the notion that these effects likely amplified the 
incidence of tumor occurrence in that study, through clonal expansion of premalignant cell 
populations that then became available for subsequent malignant transformation (Moolgavkar, 
1983; Bogen, 1989).  As further discussed below, a site-specific genotoxic MOA appears also to 
have been involved, as may be indicated by absence of nasal tumors in similarly exposed mice, 
despite evidence of (somewhat less severe) nasal epithelial hyperplasia and tissue damage (NTP, 
1992; Abdo et al., 1992).  Because a cytotoxic MOA contributed to those tumors to an unknown 
(but clearly nonzero) extent, fundamental MOA uncertainty is intrinsic to any estimate of low-
dose cancer risk associated potential genotoxicity that may also have contributed to rat nasal 
tumor formation in the NTP (2000) bioassay. 
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Naphthalene Metabolite Cytotoxicity 
 Naphthalene is metabolically activated by one or more forms of cytochrome P450 (CYP) 
to a chiral 1,2-epoxide, which can react directly to form covalent adducts with cellular 
nucleophiles such as DNA and protein, or undergo subsequent transformation to other reactive 
metabolites (including 1,2- and 1-4-naphthoquinones) or to detoxified intermediates that are 
excreted, primarily in urine (Buckpitt and Franklin, 1989; Buckpitt et al., 2002; Waidyanatha et 
al., 2002; EPA, 2004; ATSDR, 2005).  CYP-mediated metabolic bioactivation of naphthalene 
varies considerably among species and among different anatomical regions of the respiratory 
tract, and correlates with observed region-, organ- and species-specific susceptibility to 
naphthalene-induced cytotoxicity and carcinogenicity (O’Brien et al., 1985; Buckpitt and 
Bahnson, 1986; Buckpitt et al., 1992, 1995, 2002; Thornton-Manning and Dahl, 1997; Baldwin 
et al., 2004, 2005; Boland et al., 2004).   
 Glutathioine-S-transferase (GST) activity is a key barrier to cytotoxicity associated with 
reactive naphthalene metabolites, and glutathione depletion before naphthalene exposure 
enhances acute naphthalene-induced injury in mouse-lung Clara cells, which are observed to be 
early and relatively susceptible targets of cell killing that occurs at all concentrations associated 
with naphthalene-related lung tumorigenesis (Warren et al., 1982; West et al., 2000; Plopper et 
al., 2001; Phimester et al., 2004, 2005).  Greater susceptibility of cells in terminal/distal vs. upper 
lung regions to naphthalene-induced cytotoxicity in mice, or to ozone-induced cytotoxicity in 
monkeys, is not explained by regional differences in rates of glutathione resynthesis (Duan et al., 
1996).  In isolated murine Clara cells, decreased cell viability was non-detectable at naphthalene is 
substantial (≥63%) at naphthalene concentrations ≥0.5 mM, but is blocked by preincubation with 
the CYP inhibitor, piperonyl butoxide (Chichester et al., 1993).  In those isolated cells, 
incubation with a 0.5-mM concentration of naphthalene, its dihydrodiol, 1-naphthol, or 1,2-
naphthoquinone all decrease cell viability to about the same degree; however, this concentration 
of naphthalene oxide or 1,4-naphthoquinone causes even greater cytotoxicity, unblocked by 
piperonyl butoxide (Chichester et al., 1993).  In isolated mouse-lung Clara cells exposed to 
naphthalene, 1,2-naphthoquinone was one of two detected types of covalent, naphthalene-related 
protein adduct (Zheng et al., 1997).  Glutathione depletion alone appears not to explain the 
necrotic response of murine Clara cells to naphthalene; rather, ultrastructural studies indicate that 
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this cytotoxic response appears to require mitochondrial damage induced by reactive naphthalene 
metabolites (Phimester et al., 2005).  Inhaled (but not ip-administered) naphthalene induces dose-
dependent Clara cell cytotoxicity in mice, whereas the same cell type does not exhibit this 
sensitivity in rats (West et al., 2001). 
 Necrosis of bronchial epithelial (Clara) cells in mice (Tong et al., 1981; Buckpitt and 
Warren, 1983; O’Brien et al., 1985, 1989) and necrosis of olfactory epithelial cells in mice, rats 
and hamsters (Plopper et al., 1992) following intraperitoneal injection of naphthalene strongly 
indicate that metabolic activation in target tissues plays a dominant, and possibly exclusive, role 
in site-specific naphthalene cytotoxicity.  There is no evidence that unmetabolized naphthalene 
is cytotoxic. 
 Human liver microsomes convert naphthalene to its dihydrodiol intermediate at faster 
rates than mouse and rat liver microsomes (Kitteringham et al., 1996).  The human enzyme that 
is orthologous to the mouse CYP2F2 enzyme is CYP2F1.  The CYP2F1 mRNA has been 
identified in human respiratory tissues by a number of different laboratories (see Raunio et al., 
1999; Ding and Kaminsky, 2003).  The CYP2F1 enzyme is expressed in lymphoblastoid cells 
where it metabolizes naphthalene to its epoxide, albeit at very low rates (Lanza et al., 1999).  
Immunolocalization failed to detect CYP2F in rhesus macaque tissue of any kind studied other 
than nasal ethmoturbinates, where levels were 10- and 20-fold lower than in corresponding rat 
and mouse tissue, respectively (Baldwin et al., 2004).  Pooled human liver microsomes (pHLMs) 
can metabolize naphthalene to trans-1,2-dihydro-1,2-naphthalenediol (dihydrodiol), 1-naphthol 
and 2-naphthol; further pHLM metabolism of 2-naphthol produces 2,6- and 1,7-
dihydroxynaphthalene, whereas dihydrodiol and 1-naphthol are not efficiently metabolized by 
pHLMs (Cho et al., 2006). 
 
Correlation of Genotoxicity and Cytotoxicity Induced by Naphthalene Metabolites 
Prokaryotic and eukaryotic in vitro study results indicate that without metabolic activation, 
naphthalene itself does not damage DNA (Schreiner, 2003).  In contrast to the parent compound, 
naphthalene metabolites, such as 1,2- and 1,4-naphthoquinone, were found to be positive for 
genotoxicity in a relatively small subset of prokaryotic and eukaryotic in vitro studies involving 
metabolic activation (Arfsten et al., 1994; Flowers-Geary et al., 1996; NTP, 1992; Wilson et al., 
1995, 1996; Sasaki et al., 1997; Yu et al. 2002; Schreiner, 2003).  The clearest evidence for this 
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involved human lymphoid cells exposed to 1,2- and/or 1,4-naphthoquinone.  After 2 hours of 
exposure to 0.1 µg/mL (0.63 µM) 1,4-naphthoquinone, MCL-5 human B-lymphocytes (which 
express several transfected CYP and epoxide hydrolase genes) exhibited a significant (~2-fold) 
increased frequency of micronuclei, but not of mutation frequency at the TK– or the HPRT– locus 
assayed (Sasaki et al., 1997).  The mutation assay performed was associated with substantially 
decreased (66 ± 20%) cell survival, but not the micronuclei assay.  Human mononuclear 
lymphocytes (MNL) exposed to various concentrations of naphthalene, 1,2-epoxynaphthalene, 1-
napthol, 1,2- naphthoquinone or 1,4-naphthoquinone were assayed for glutathione (GSH) 
depletion, for cytotoxicity and for sister chromatid exchange (SCE) frequency by Wilson et al. 
(1996).  Exposure for 2 hours to the 1-napthol metabolites, 1,2- naphthoquinone or 1,4-
naphthoquinone, were observed to be directly toxic to MNL and to deplete GSH to up to 1% of 
control levels (Wilson et al., 1996).  Cytotoxicity data from this study, replotted in Figure 1, 
indicate that cell killing by both of these naphthalene metabolites is modeled reasonably well as 
a linear function of log concentration.  Note that the relationship shown in Figure 1 predicts the 
average amount of cell killing observed for cells exposed to 0.1 µg/mL = 0.63 µM 1,4-
naphthoquinone, by Sasaki et al., 1997. 
 
Figure 1.  Increased fraction F(c) of MNL 
killed by a 2-hour exposure to different 
concentrations c of either 1,2- or 1,4-
naphthoquinone, based on data reported by 
Wilson et al. (1996), modeled as F(c) = [P(c) – 
P(0)]/[1–P(0)] = 0.201 (± 0.011) + 0.0749 (± 
0.0051) log(c), where P(0) ≈ 2.5%, and 
parameter estimates (±1 SE) were obtained by 
iteratively reweighted least-squares linear 
regression (Carrol and Ruppert, 1988), 
assuming measurement errors equal 
approximately one sixth of each reported 
measure (indicated by plotted error bars).  
Goodness of fit statistics are shown. 
 
 SCE frequencies reported in Figure 5 of Wilson et al. (1996) for similarly exposed MNL 
cells relative to control cells is likewise well modeled (by unweighted linear regression) as the 
following linear function of log concentration:  Fold-increase in SCE/chromosome = 1.006 (± 
0.038) + 0.055 (± 0.0013) log(c) (R2 = 0.998, p = 0.018 for a zero-slope null hypothesis), based 
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on SCE data obtained for each naphthoquinone at 1, 10 and 100 µM concentrations.  Combining 
this relationship with that shown in Figure 1 above (with Y-intercept assumed to be unity) yields 
an estimated relation between relative risk (RR) of MNL cell death, modeled as RR = 1/[1–F(c)], 
and corresponding RR for SCE-equivalent DNA damage or mutation, shown in Figure 2.  This 
relationship implies that any substantial increase in the background rate of critical DNA damage 
from the most potent of genotoxic metabolites that may arise from exposure to naphthalene is 
predicted to be accompanied invariably by substantially increased likelihood of cell death due to 
cytotoxicity.  Notably, naphthalene 1,2-epoxide (2 hours at 1 to 100 µM) was found in the same 
study to cause neither GSH depletion, cytotoxicity, nor SCE induction (Wilson et al., 1996).  
Cytotoxicity was observed in MNL exposed for 2 hours to 10 or 100 µM concentrations of either 
naphthalene and 1-naphthol in the presence of rat liver microsomes, but the response to              
1-naphthol (approaching that due to equal concentrations of 1,2- or 1,4-naphthoquinone) far 
exceeded that to naphthalene (Wilson et al., 1996). 
 
 
Figure 2.  Relative risk (RR) of cell death as a 
function of RR of SCE-equivalent DNA damage 
or mutation, inferred from cytotoxicity and SCE 
data gathered by Wilson et al. (1996) on MNL 
cells exposed to naphthoquinones.  The modeled 
relationship is RRdeath = Max(1, 1/[0.5280–
log(RRmut–1)/13.358]). 
 
 
 
 The pattern shown in Figure 2 exhibits a strong, non-threshold-like correlation similar 
that observed between genotoxicity and cytotoxicity exhibited by other classes of mutagenic, 
carcinogenic and antineoplastic agents, such as chemical alkylating agents (Sanderson et al., 
1991) and ionizing radiation (Stewart, 2001). 
 
Site- and Species-Specific Naphthalene Cytotoxicity is Predicted by PBPK Modeling 
 As mentioned above, the necrotic response of murine respiratory Clara cells to 
naphthalene appears to require not only glutathione (GSH) depletion, but also mitochondrial 
damage induced by reactive naphthalene metabolites (Phimester et al., 2005).  Physiologically 
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based pharmacokinetic (PBPK) models developed for naphthalene (Sweeney et al., 1996), and 
for naphthalene and its 1,2-epoxide metabolite and associated reaction products (Quick and 
Shuler, 1999; Ghanem and Shuler, 2000; Willems et al., 2001), have been proposed to describe 
and explore plausible measures of biologically effective dose pertaining to naphthalene toxicity 
and carcinogenicity.  PBPK model parameters governing naphthalene metabolism for the earlier 
models were estimated entirely from in vitro metabolic data, and then were compared and/or 
partially optimized to previously published data on levels of naphthalene in blood, tissue-specific 
GSH, and 14C-radiolabeled adducts covalently bound to tissue-specific macromolecules in mice 
and rats exposed in vivo to naphthalene by intravenous (iv) injection, intraperitoneal (ip) 
injection, or oral dosing (Sweeney et al., 1996; Quick and Shuler, 1999; Ghanem and Shuler, 
2000).  The Quick and Shuler (1999) model, summarized in Figure 3, predicts detailed, time-
dependent patterns of covalent binding and GSH depletion in lung and in liver of mice 
administered naphthalene by ip injection that were shown to be reasonably consistent with a 
range of previously published data, including detailed data reported by Warren et al. (1982) for 
mice ip-injected with radiolabeled naphthalene. 
 
Figure 3. The flow-limited 
PBPK model of Quick and 
Shuler (1999) describing 
uptake, distribution and 
metabolism of naphthalene.  
Arrows denote flows, dashed 
arrows CYP-mediated 
metabolic transformation 
(Kidney and Other compart-
ments were referred to as 
Richly and Poorly Perfused 
compartments, respectively).  
In the related Willems et al. 
(2001) model, each naphthalene 
compartment is split into two 
corresponding diffusion-limited 
subcompartments: one each for 
the tissue and its capillary bed. 
 
 
 The Willems et al. (2001) model modified the Quick and Shuler (1999) model in two 
ways.  First, all naphthalene-specific model compartments were restructured to reflect a 
“distributed blood” assumption that intra-compartment naphthalene distribution is limited by 
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diffusion rather than by blood flow (i.e., perfusion).  The “distributed blood” framework was 
developed by Kohn (1997), who showed this approach to provide a more realistic model the 
kinetics of respiratory 1,3-butadiene uptake by mice.  Second, Willems et al. (2001) replaced the 
submodel for glutathione (GSH) turnover used by Quick and Shuler (1999) with the generic 
GSH model incorporated into the PBPK model otherwise developed specifically for 1,3-
butadiene (Kohn and Melnick, 2000).  Using this modified PBPK model, Willems et al. (2001) 
estimated parameters governing CYP-mediated naphthalene metabolism in both liver and lung 
by fitting model predictions for naphthalene in chamber air in rats exposed for 6 hours (once, or 
daily for two weeks) to concentrations of 10, 30 or 60 ppm naphthalene, and for in naphthalene 
in blood of mice exposed for 6 hours (once, or daily for two weeks) to concentrations of 10, 30 
or 60 ppm naphthalene—i.e., using respiratory exposure protocols similar to those used in the 
NTP (1992, 2000) rodent bioassays that indicated positive carcinogenicity. 
 Willems et al. (2001) showed that their model fairly accurately predicted their newly 
obtained in vivo data on naphthalene uptake and distribution in rats and mice.  This model also 
provides predictions of tissue-specific GSH depletion that appear to provide some insight into 
why lung might be much more susceptible to naphthalene-induced cytotoxicity than liver.  
Figure 4 shows tissue-specific relative GSH concentrations predicted by the Willems et al. 
(2001) model in 0.5-kg male rats exposed for 6 hours to 10 ppm naphthalene by inhalation.  This 
model consists of the system of linear and nonlinear ordinary differential equations and 
parameter definitions defined by Willems et al. (2001) and papers cited therein, here 
implemented using Mathematica 5.0® software (Wolfram, 1999).  Figure 4 (left panel) shows 
that this model predicts rapid GSH depletion in lung, but not in liver—very similar to (but with 
greater detail over a 6-hour period than) predictions summarized for similarly exposed (~0.14-kg 
female) rats in the upper left and right panels of the “Figure 5” that appears in the study by 
Willems et al. (2001).  That figure from that study (in contrast to the 6-hour time frame indicated 
in Figure 4) showed results corresponding to a 5 day/week pattern of 6-hour respiratory 
exposures over a 3-week period, demonstrating that repeated previous exposures have very little  
effect on tissue-specific levels of GSH depletion predicted after 6 hours of respiratory exposure 
to naphthalene. 
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Figure 4.  Glutathione (GSH) concentrations predicted by the PBPK model of Willems et al. (1999) for 
rats exposed to naphthalene in air, relative to those in non-exposed animals, in liver (red curve) and lung 
(blue curve). (Left) GSH levels predicted in rats exposed to 10 ppm naphthalene as functions of time; 
(right) GSH levels after 6 h of respiratory exposure as a function of naphthalene air concentration. 
 
 Species- and site-specific predictions of cytotoxicity based on PBPK modeling can 
provide a mechanistic, experimentally testable basis for toxicokinetic models applicable to 
cancer risk extrapolation.  In view of data indicating the critical role of GSH depletion in 
cytotoxicity that can be induced by naphthalene or its metabolites discussed earlier, PBPK-model 
predictions of species-, sex- and site-specific differences in such GSH-depletion offer critical 
mechanistic insight into the potential role that cytotoxicity may have played in dose-response 
observed in naphthalene cancer bioassays.  However, a prerequisite for such interpretation is 
PBPK model validation that includes reasonable agreement with a range of relevant experimental 
observations.  In this regard, GSH predictions like those shown in Figure 4 are highly 
questionable in view of the fact that analogous predictions made by the Willems et al. (2001) 
model for mice exposed to 200 mg/kg naphthalene by ip injection (Figure 5) deviate markedly 
from relative GSH measures reported by Warren et al. (1982) (reprinted in Figure 6 below).  In 
particular, note the substantially different appearance between predicted tissue-specific temporal 
patterns of GSH level shown in Figure 5 (left) vs. corresponding data shown in Figure 6 (panels 
a and c), and likewise between predicted tissue-specific patterns of GSH level as functions of 
dose shown in Figure 5 (right) vs. corresponding data shown in Figure 6 (panels e and g).  The 
WQSM model differs from that of Willems et al. (2001) in the following four ways, which are 
further described below: (1) different values are used for certain GSH-related parameters, (2) a 
different structure of the GSH-turnover submodel is used, (3) kidney was added to (liver and 
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Figure 5.  Glutathione (GSH) concentrations predicted by the PBPK model of Willems et al. (1999) for 
mice ip-injected with naphthalene, relative to that in non-exposed animals, in liver (red curve) and lung 
(blue curve). (Left) GSH levels predicted in mice ip-injected with 200 mg/kg naphthalene as functions of 
post-injection time; (right) GSH levels 4 h after ip injection as functions of naphthalene dose. 
 
lung) compartments in which GSH conjugation to naphthalene oxide is presumed to occur 
mediated by glutathione-S-transferase (GST) activity, and (4) a different assumption was used 
concerning the uptake of naphthalene administered by ip injection.   
 For the WQSM model, values of selected GSH submodel parameters were changed to 
correspond to those measured in 20- to 25-g male Swiss-Webster mice exposed by Warren et al. 
(1982) to naphthalene by ip injection.  Specifically, the values 1800 and 7500 µM listed by 
Quick and Shuler (1999), and used by Willems et al. (2001), for the parameter (
! 
C
x
GSHss) 
specifying steady-state GSH concentration in mouse tissue x for x = lung and liver, respectively, 
were replaced by 706, 2434 and 1420 µM for x = lung, liver and kidney, respectively, which are 
the corresponding reported mean values of measures made by Warren et al. (1982).  The values 
2750 and 280 µM/min listed by Quick and Shuler (1999), and used by Willems et al. (2001), for 
the parameter (
! 
V
max,x
GST ) specifying the maximal rate of GST-mediated GSH conjugation to 
naphthalene oxide in the mouse tissues x = lung and liver, respectively, were replaced by 200, 
1000 and 200 µM/min for x = lung, liver and kidney, respectively, determined by qualitative 
optimization of WQSM model predictions to tissue-specific GSH data of Warren et al. (1982).  
Likewise, the values 26.4, 102 and 75.6 nmol/mg/hr cited by Kohn and Melnick (2000), and used 
by Willems et al. (2001), for the parameter (
! 
V
max,x
GGS ) specifying the maximal rate of GSH synthesis 
by γ-glutamyl synthetase (GGS) in the mouse tissues x = lung and liver, respectively, were 
replaced by 80, 85 and 30 nmol/mg/hr for x = lung, liver and kidney, respectively, again each 
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Figure 6.  Tissue-specific levels of covalent binding (left axes) and relative glutathione (GSH) depletion 
(right axes) reported by Warren et al. (1982; in Figures 2 and 3 from that study) and by Buckpitt and 
Warren (1983) for 20- to 25-g male Swiss Webster mice ip-injected with 14C-radiolabeled naphthalene. 
(Panels a-d) levels predicted in mice ip-injected with 200 mg/kg naphthalene as functions of post-
injection time; (panels e-h) levels 4 h after ip injection as functions of naphthalene dose.  Note the 
substantially nonlinear, upward bend in dose-response covalent binding, and associated GSH depletion 
≥50%, observed to occur in all tissues at doses ≥ ~200 mg/kg (panels e-h).  This “hockey-stick” dose-
response pattern is consistent with dose-related saturation of GSH-mediated deactivation of reactive 
naphthalene metabolites. 
a b 
c d 
e f 
g h 
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 Although, as noted above, experimental data reported by Warren et al. (1982) were 
modeled fairly well by the flow-limited PBPK model of Quick and Schuler (1999), the 
parameters governing CYP-mediated naphthalene metabolism used in that model were estimated 
directly from in vitro rather than in vivo data, and it moreover relied on potentially unrealistic 
submodel structures for GSH-turnover and for tissue-specific naphthalene partitioning.  These 
issues were all addressed in the model of Willems et al. (2001), but this presumably more 
realistic model evidently fails to predict key empirical data that were predicted fairly well by the 
Quick and Schuler (1999) model.  It is not clear whether or to what extent Willems et al. (2001) 
intended their PBPK model to agree with specific sets of previously published experimental data 
concerning naphthalene metabolites or GSH depletion, vs. provide an initial basis for model 
development and exploration, since that study included only comparisons between predictions 
made by their model and corresponding sets of in vivo data they reported for chamber-air or 
blood concentrations of naphthalene in mice or rats exposed to naphthalene by inhalation or by 
iv injection. 
 A slightly modified version of the PBPK model of Willems et al. (2001), henceforth 
referred to as the WQSM model, does indeed predict GSH levels (Figure 7) reasonably close to 
those measured by Warren et al. (1982) in lung, liver and kidney (Figure 6).  The WQSM model 
is identical in all respects to all aspects of the Willems et al. (2001) “distributed blood” model 
that pertain directly to naphthalene uptake, distribution and metabolism (i.e., the part of their 
overall model summarized by “Naphthalene” components shown on the left side of Figure 3). 
 
 
Figure 7.  Glutathione (GSH) concentrations predicted by the WQSM model for 20- to 25-g male mice 
ip-injected with naphthalene, relative to those in vehicle-exposed animals, in liver (red), lung (blue) and 
kidney (green). (Left) GSH levels predicted in mice ip-injected with 200 mg/kg naphthalene as functions 
of post-injection time; (right) GSH levels 4 h after ip injection as functions of naphthalene dose. 
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determined by qualitative optimization of WQSM model predictions to tissue-specific GSH data 
of Warren et al. (1982). 
 Parameter values used for rats were unchanged, except that the values 1800 and 7500 µM 
listed by Quick and Shuler (1999), and used by Willems et al. (2001), for the parameter (
! 
C
x
GSHss) 
specifying steady-state GSH concentration in rat lung and liver, respectively, were replaced by 
2500, 10000 and 2000 µM for x = lung, liver and kidney, respectively, based on corresponding 
daytime measures in male Sprague-Dawley rats reported by Farooqui and Ahmed (1984). 
 While all active mammalian cells use GSH to bind oxidative products of mitochondrial 
and cytosolic metabolism, key metabolizing tissues (including liver, kidney, lung and intestine) 
synthesize and maintain comparatively high GSH concentrations, with liver being a primary 
source of GSH exported in systemically circulating blood (in which 98% of the GSH is 
contained in red blood cells), from which GSH is transported to and extracted by other organs—
principally in the kidney—as a primary source of cysteine used for (e.g., GGS-mediated) 
intracellular GSH resynthesis (Dass et al., 1992; Lohr, 1998; Lash, 2005).  The kidney is among 
mammalian tissue types that express the greatest levels of GST-specific mRNA, reflecting 
relatively high GSH turnover in these tissues as one of the key mechanisms cells use to 
effectively inhibit oxidative stress that may arise from a variety of normal and pathological 
processes (Estonius et al., 1999; Forsberg et al., 2001). 
 A PBPK model of naphthalene oxide (NO) that omits its elimination via GSH-
conjugation in kidney is thus unlikely to be realistic, particularly in view of covalent binding and 
GSH depletion in kidney tissue of mice (but not rats) exposed to a sufficiently high dose of 
naphthalene (see, e.g., Warren et al., 1982; Buckpitt and Warren, 1983; O’Brien et al., 1985).  In 
the WQSM model, this process is reflected by subtracting from the expression used to model the 
rate dNOx(t)dt (the time derivative of NO concentration in tissue x, with x = kidney), the same 
form of x-specific (“ping-pong” saturation kinetics) term as those used by Quick and Shuler 
(1999) and Willems et al. (2001) to denote rates of GGS-mediated NO-loss in expressions 
representing dNOx(t)dt for liver and lung.  This term also appears in tissue-specific GSH-
turnover submodels used by Willems et al. (2001), based on the generic model described by 
Kohn and Melnick (2000), where this term was denoted 
! 
vsynthesis
GSH, x , except that specificity to tissue x 
appears explicitly in the latter notation.  Likewise, x-specific expressions for the rates dGSHx(t)dt 
and dCysx(t)dt of change in concentration of GSH and its cysteine precursor, respectively, 
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contained in tissue x was added for x = kidney, using forms identical to those used for lung and 
liver tissues by Quick and Shuler (1999) and Willems et al. (2001), except that in the WQSM 
model, each calculated rate constant for cysteine uptake (denoted 
! 
vup
Cys, x  used in the GSH-
turnover model of Kohn and Melnick, 2000) is multiplied by a corresponding term Sx(t) assumed 
to be proportional in the following way to the ratio Rx(t) = 
! 
C
x
GSHss /GSHx(t) (i.e., to the magnitude 
of tissue-specific GSH depletion at time t): 
 
 Sx(t)  = 
! 
Min W
x
R
x
(t)[ ]
nx
, b( )    , (1) 
 
where exponents nx were assumed to be fixed at values of 1.5, 1.5 and 8 for x = lung, liver and 
kidney, respectively; and Wx = 1 with upper bound b = 5 were assumed for x = lung and liver.  
The Sx(t) term represents an assumption that active-transport-mediated uptake of extracellular 
cysteine actively responds to GSH depletion by increasing above its initial value 
! 
vup
Cys, x  to a rate 
proportional to a power of Rx(t) but ≤ b
! 
vup
Cys, x . Finally, only for x = kidney, the (1 + GSHx(t)/Ki) 
term used in the GSH-metabolism model of Kohn and Melnick (2000) was replaced by the more 
responsive “ping-pong” saturation term, [GSHx(t)/
! 
C
x
GSHss]2. 
 Using Wkidney = 1, this revised GSH-turnover model was found to be unable to fit the 
empirical kidney GHS data obtained by Warren et al. (1982), predicting only a gradual decline, 
instead of the observed sharp decline, in mouse kidney GSH at ip naphthalene doses 
>200 mg/kg.  The observed sharp decline near that dose would, however, be explained if GSH in 
circulating blood—which is continuously extracted as a cysteine source by the kidney (Dass et 
al., 1992; Lash, 2005)—were proportional to GSH in liver, such that whenever GSH in liver (and 
consequently, in blood) becomes depleted below a critical threshold fraction f, cysteine 
extraction by the kidney becomes sharply reduced.  In the WQSM model, this assumption is 
reflected for x = kidney by setting Wx = 5[Rx(t)/f]–nx for all [Rx(t)]–1 < f, and Wx = 1 otherwise, 
with f = 40%. 
 Finally, Quick and Schuler (1999) assumed that ip-injected naphthalene is absorbed 
entirely by the liver within one minute.  The WQSM model assumes instead that only a fraction 
fliv of ip-injected naphthalene is absorbed directly into liver tissue with an absorption half-time of 
150 min, while the remaining fraction (1– fliv) is absorbed entirely into the “Other” (slowly 
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perfused) compartment (see Figure 3) with an absorption half-time of 30 min. 
 The final GSH-turnover model described predicts temporal and dose-dependent patterns 
of relative GSH content in liver, lung and kidney (Figure 6) that are all reasonably similar to the 
corresponding patterns (Figure 7) observed by Warren et al. (1982).  Figure 8 shows 
corresponding WQSM model predictions for mice and rats that continuously inhale naphthalene 
at a specified air concentration for a total of 6-hour.  This single-pulse respiratory exposure 
scenario yields results very similar to those obtained using the repeated-exposure scenario used 
in the mouse and rat bioassays done by NTP (1992, 2000).  (As noted earlier in discussing 
Figure 4, although daily 6-hour exposures were used 5 days/week in those bioassays, the impact 
of repeated exposures on tissue-specific dynamic equilibria achieved is estimated to have been 
minimal.)  For mice, the model predicts moderate GSH depletion in liver and kidney, and nearly 
complete GSH depletion in lung, at all naphthalene concentrations exceeding about 0.1 ppm 
(Figure 8, left).  Assuming nasal naphthalene concentrations achieved were similar to those in 
lung, and that nasal epithelial tissues in mice are at least as sensitive to naphthalene cytotoxicity 
as those in the lung, this pattern is consistent with substantial inflammation and evidence of 
cytotoxic/hyperplastic response observed in these tissues in some or nearly all bioassay mice at 
both exposure levels used, 10 and 30 ppm, with no such evidence in any other tissue at either 
exposure level (Abdo et al., 1992; NTP, 1992). 
 
    
Figure 8.  Glutathione (GSH) concentrations predicted by the WQSM model for 22.5-g male mice and 
for 0.5-kg male rats exposed continuously for 6 h by inhaling the indicated air concentration of 
naphthalene, relative to those in vehicle-exposed animals, in liver (red), lung (blue) and kidney (green). In 
the plot for rats (right), in each set of red and blue curves, the lightest and uppermost curve corresponds 
to the base-case WQSM model, and the corresponding pair of progressively lower/darker curves reflect 
assumed increased maximum rates of CYP metabolism in lung by factors of 2 and 3, respectively. 
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 For rats, the WQSM model predicts that severe GSH depletion will not occur in kidney, 
liver or lung at any exposure level up to 100 ppm naphthalene, which is consistent with absence 
of cytotoxic effects observed in any of these tissues in bioassay rats exposed daily to 6-hour 
levels of 10, 30 or 60 ppm naphthalene (NTP, 2000; Abdo et al., 2001; Long et al., 2003).  The 
pattern of GSH response to 6-hour naphthalene exposures in rat lung (Figure 8, right) suggests 
that any rat tissue that might be exposed to concentrations similar to those in lung, but also 
produce reactive naphthalene metabolites more than about twice as rapidly as lung, would result 
in nearly complete GSH depletion, and thus be expected to incur cytotoxicity due to concurrent 
exposure to reactive naphthalene metabolites (e.g., 1,2- and/or 1,4-naphthoquinone) at 
naphthalene concentrations ≥ 1 ppm.  In the NTP rat bioassay, nearly all rats in all (10-, 30- and 
60-ppm) exposure groups exhibited cytotoxic effects reflected by evident areas of cell killing, 
metaplasia, and mild to moderate hyperplasia in respiratory and olfactory nasal epithelia (NTP, 
2000; Abdo et al., 2001; Long et al., 2003).  These bioassay results, combined with the WQSM 
modeling results described, provide arguably convincing support for the hypothesis that a 
substantial subset of cells contained in rat respiratory and olfactory nasal epithelia (perhaps 
analogous to Clara cells in mouse bronchial epithelium) have a greater capacity to metabolize 
naphthalene to reactive intermediates than is present in rat lung tissue.  This hypothesis could be 
developed more explicitly and be tested by adapting for application to naphthalene PBPK models 
that incorporate nasal compartments and dynamic nasal tissue dosimetry (Anderson et al., 2000; 
Frederick et al., 2002; Sarangapani et al., 2002; Sweeny et al., 2004), parameterized using 
species-specific data on GSH depletion and covalent binding in nasal tissues exposed in vivo to 
different naphthalene concentrations in air. 
 
Biologically Based (MVK) Modeling to Bound MOA Uncertainty 
 Biologically based stochastic 2-stage models of carcinogenesis provide a mechanistic 
framework for understanding and modeling the impact on cancer risk of dynamic exposures to 
environmental agents that affect rates of critical stem-cell mutations, and rates of stem-cell birth 
and/or death (Moolgavkar and Knudsen, 1981; Moolgavkar, 1983; Bogen, 1989).  This 
framework is consistent with the large body of experimental and epidemiological data supporting 
the view that genotoxicity as well as altered cell-growth kinetics each play critical roles that may 
affect environmental carcinogen dose-response (Cohen and Ellwein, 1990, 1991; Ames and 
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Gold, 1990; Ames et al., 1993; Hanahan and Weinberg, 2000)  The “MVK” model of 
carcinogenesis (Moolgavkar, 1983) posits occurrence of incipient cancer cells as a doubly 
stochastic filtered Poisson process, whereby normal epithelial stem cells can each by mutation at 
mean rate m1 give rise to a premalignant cell, which each may proliferate clonally (by cell 
division at birth rate r and cell death/differentiation at rate d) or give rise by mutation at mean 
rate m2 to a malignant cell.  Stem cells likewise undergo cell birth and death/differentiation, 
which may affect the number N of stem cells at risk for transformation over time. 
 Assuming approximately constant N for post-neonatal epithelial (excluding delayed-
growth-phase, such as mammary) tissue, and assuming equality among stage-specific 
background mutation rates (setting m = m1 = m2), the 2-stage stochastic MVK model applied 
here used piecewise-constant parameters, which during each ith interval (for i = 1,2) involve 
corresponding rates of mean occurrence (Nmi), birth (bi), death (di), and mutation (mi) of 
premalignant cells.  The tumor data modeled were data concerning nasal respiratory epithelium 
adenomas (NREA) in male rats, and nasal olfactory epithelium neuroblastomas (NRON) in 
female rats, exposed to 60 ppm naphthalene for 6 hours/day, 5 day/week beginning at 6 weeks of 
age, from the NTP (2000) bioassay discussed above.  The highest (60-ppm) exposure level 
provides maximum power to compare model results with empirical survival data (summarized in 
Appendix C of EPA, 2004), in view of substantial exposure-related mortality that occurred in 
both sexes in this exposure group.  From historical data pertaining to occurrence of these tumors 
in control NTP rats (Copely, 2000; NTP, 2002; NTP 2006), the background incidence rate of 
NREA in male rats was estimated to be 2/4000 (0.05%), while that of NRON in female (and 
male) rats was estimated to be less than 0/4000, which for the purpose of this analysis was 
approximated as 0.01%.  These very low background rates of tumor incidence, combined with 
the lifetime (105-week) bioassay duration for rats, severely constrain biologically plausible 
parameterizations of any MVK model applied to explain tumor incidence rates observed in both 
the control and exposed animals.  For each tumor type, this model can be applied under three 
alternative MOA assumptions (denoted by the indicated MOA type): (G) a purely genotoxic 
MOA (GMOA) driven by a dose-related change in m, (C) a purely nongenotoxic/cytotoxic MOA 
(CMOA) driven by a dose-related change in b in response to induced killing and replacement of 
stem cells, or (D) a dual or mixed MOA (DMOA) involving joint/simultaneous operation of both 
MOA types G and C.  Conditional on very low tumor background rates, the divergence in model 
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predictions made by these different MOA assumptions can be used to assess the extent to which 
model G, in particular, may be implausible.  In the case of naphthalene-induced nasal tumors in 
rats, there is arguably convincing evidence that model G cannot possibly be true in a strict sense, 
based on the histological evidence of tumor-site-specific inflammation and hyperplasia in the rat 
nasal epithelium, detailed toxicokinetic data on naphthalene-metabolite cytotoxicity, in vitro data 
clearly implying that naphthalene-metabolite genotoxicity is invariably associated with increased 
likelihood of cell death in affected cell populations, and related PBPK modeling discussed 
above.  However, evidence for naphthalene-metabolite genotoxicity likewise questions the 
plausibility of model C for naphthalene-induced rat nasal tumors.  A lower bound on the 
magnitude of MOA uncertainty associated with model C can be obtained by comparing the 
elevated level of rat tumor risk to which all models (including C have been fit), to the reduced 
level of risk predicted by the most C-like of biologically plausible model-D fits made conditional 
on the absence of dose-related cytotoxic effects, which effects are not consistent with a (e.g., 
default regulatory GMOA) assumption and would be expected to be negligible at very low levels 
of environmental exposure. 
 To illustrate this idea of bounding uncertainty in naphthalene carcinogenic MOA using 
the MVK framework, the following biologically realistic assumptions were used concerning 
model parameter values and parameter interrelationships applicable to this compound.  As 
mentioned above, equality was assumed for stage-specific background mutation rates (m0).  
Values of N were presumed to be approximately 108 for nasal epithelial stem cells of each tumor 
type.  Biologically plausible values for m0 were presumed to be between 10-8 and 10-7 y-1, i.e., 
similar to estimated values pertaining to humans (Trainor et al., 1984; King et al., 1994; 
Mendelsohn, 1990; Robinson et al., 1994).  The background rate b0 of stem-cell division for 
nasal epithelium was assumed to be 1 y-1, based on labeling indices <1% observed in basal 
lamina that serve as stem-cell reservoirs for rat nasal epithelial tissues (Monticello et al., 1990; 
Hotchkiss et al., 1997).  Potential linear functional dependence of m on b, implied in the formal 
MVK model (Moolgavkar, 1983) and also by experimental evidence (Ames et al., 1993), was 
ignored here in view of the relatively minor quantitative impacts (of order [Δb]2) such functional 
dependence can have, which in turn is due to relatively large impacts on risk that the MVK 
model predicts may arise from any relatively small (e.g., cytotoxicity-related) change (Δb) in 
value(s) of b.  Equal background rates of stem-cell birth and death were assumed, reflecting the 
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assumed, approximately constant value of stem-cell number N over the modeled post-natal rat 
lifespan (105 weeks).  Premalignant cells generating NREA were assumed under normal 
conditions to proliferate at elevated rates of n b0 assuming n = 5, consistent with n-fold 
(hyperplastic) elevation in turnover rates with observed values of n between 5 and 20 in putative 
premalignant cells that are histologically identifiable (Rotstein et al., 1986; Dragan et al., 1993; 
Zerban, 1994), as well as in nasal polyps (Coste et al., 1996).  It was assumed that n = 1 for 
premalignant cells generating NRON, consistent with the observation that neuroendocrine cells 
and associated neuroepithelial bodies in mouse bronchiolar epithelium show very little if any 
mitotic activity and appear to be relatively resistant to chemically induced cytotoxicity (Ogawa 
et al., 1993). 
 In all MVK models considered, premalignant cells in bioassay-exposed animals were 
assumed to be by some factor K less sensitive to cytotoxic effects of reactive naphthalene 
metabolites, in accordance with observations that repeated inhalation exposures to the 
naphthalene produce airway-specific Clara Cell tolerance in mouse bronchiolar epithelium (West 
et al., 2000a-b, 2003).  Such induced, airway-specific Clara Cell tolerance in mouse bronchiolar 
epithelium was previously observed after bromobenzene exposure (Ogawa et al., 1993), and is 
generally similar to exposure-induced resistance of hepatocytes to styrene toxicity observed to 
develop in B6C3F1 mice (Mahler et al., 1999), resistance of murine lung tumor cells to 
cytotoxicity induced  by xenobiotics including naphthalene (Fokert et al., 1992), and resistance 
to cytotoxic drugs observed in leukemic cells (Maung et al., 1994).  Intrinsic and/or induced 
heterogeneity in GSH levels appears to play an important role in NAP susceptibility of Clara 
cells (West et al., 2000a-b), as has also observed as a basis for cytotoxic resistance in leukemic 
cells (Maung et al., 1994); however, one or more of many other known cellular strategies to 
reduce oxidative stress (Forsberg et al., 2001) may also be involved.  In view of at least 4-fold 
variation observed in murine bronchiolar Clara-cell glutathione levels (West, 2000b), and absent 
more informative data on this point, a susceptibility-reduction factor of K = 10 was assumed in 
this analysis.  In view of the strong correlation between naphthalene-metabolite genotoxicity and 
cytotoxicity (Figure 2), the factor K was assumed also to apply to exposure-induced mutation. 
 In model G, the mutation rate m was assumed to increase over background rate m0 by a 
dose-dependent factor M in stem cells, and by the factor [1 + (M–1)/K] in premalignant cells, 
with M = 1 for where M = 1 under unexposed conditions.  In model C, tissue response to dose-
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related cell killing, the birth rate was assumed to increase over background rate b0 by a dose-
dependent factor B in stem cells, and by the factor (n + B – 1) in premalignant cells, where B = 1 
under unexposed conditions.  A background death rate of b0 is assumed in stem and premalignant 
rate was assumed increase B-fold over its background rate b0 assumed in stem cells, which is 
assumed to increase in premalignant cells by the factor [n + (B–1)/K].  In model D, it was 
assumed that C- and G-specific contributions to a DMOA are governed mechanistically by the 
empirical relationship between cytotoxicity and mutation, B = Max(1, 1/[0.5280–log(M–1)/ 
13.358] plotted in Figure 2, based on in vitro data for the most potent mutagenic naphthalene 
metabolites yet identified, 1,2- and 1,4-naphthalene epoxide.  Model D* shall denote model D 
conditional on B = 1, representing model D in the absence of any dose-related cytotoxic effect on 
MVK-model parameter b.  Model D* illustrates the magnitude of risk predicted by model D that 
is attributable only to mutagenic effects. 
 Models conditional on corresponding background-rate fits were fit to raw, observed high-
dose data for NREA and NRON incidence rates after first deleting data pertaining to animals that 
died before the occurrence of each corresponding tumor type (12/48 female NRON, 15/41 male 
NREA; from Appendix C of EPA, 2004) and adjusting to the corresponding “Poly-3” estimate of 
tumor incidence (28.2% female NRON, 38.1% male NREA; from p. 30 of NTP, 2002).  The 
adjusted time-specific tumor-incidence rates were used to estimate the corresponding survival 
function for exposed animals with each tumor type.  To fit each MOA-specific model to an 
adjusted, elevated tumor-incidence rate, a single corresponding MOA-specific parameter was 
optimized conditional on other parameter values considered biologically plausible as discussed 
above.  Model calculations were performed using the analytic approach of Zheng (1995), 
implemented using Mathematica 5.0® software (Wolfram, 1999). Optimization in each case 
yielded a unique univariate model fit (m0 to fit background rates, and depending on model type, 
either M and/or M to fit elevated rates), conditional on fixed values of the other MVK parameters 
described above, since the MVK-type hazard function with at most three piecewise-constant 
parameters is identifiable (Heidenreich et al., 1997). 
 Model fits obtained for each tumor type are summarized in Table 1 and plotted in 
Figure 9.  Each tumor-specific plot shows that model G (blue curve) diverges greatly from model 
C (red curve), with model D generally falling between models C and G at all times points shown.   
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Table 1.  Summary of MVK model fits to control and high-dose rat nasal tumor data. 
 
Model parametersb 
Tumor typea 
Exposure 
group Model(s) 
m0 
(×10-7) M B 
Control All 1.579 1 1 
60 ppm G [1.579] 118.8 1 
60 ppm C [1.579] 1 5.734 
NREA 
60 ppm D [1.579] 27.99 [2.982] 
      
Control All 7.004 1 1 
60 ppm G [7.004] 188.5 1 
60 ppm C [7.004] 1 7.983 
NRON 
60 ppm D [7.004] 61.76 [3.642] 
a NREA = nasal respiratory epithelium adenomas in male rats, NRON = nasal olfactory epithelium 
neuroblastomas (NRON) in female rats. 
b The single, parameter in each row is shown non-bracketed and to 4 significant digits was obtained 
conditional on all other parameters in that row.  Note that in model D, parameter B is modeled as the 
dependent function of M shown in Figure 2. 
 
 
    
Figure 9.  MOA-specific MVK models of NREA and NRON tumor incidence in NTP bioassay rats.  In 
each plot, the bold black (lowermost) curve shows the baseline MVK model fit to the indicated control 
tumor incidence rate, to which baseline all of the models considered collapse at zero dose; the bold blue 
(uppermost), red and green curves show models G, C and D, respectively; and the light green curve shows 
model D*.  The jagged light black step function is the approximate survival function based on 
corresponding adjusted empirical bioassay survival data. 
 
NREA NRON 
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Model D also appears to be somewhat more consistent with the empirical survival function for 
each tumor type.  The value of model D* at week 105 indicates that a genotoxic component 
represents about 8.6% and 13.5% of the total tumor incidence explained by model D for NREA 
and for NRON, respectively. 
 Model D reflects a mechanistic explanation of the modeled bioassay results that is 
reasonably consistent with multistage cancer theory and the large amount of in vivo and in vitro 
toxicokinetic data that clearly establish that cytotoxicity did play some role in elevating the rates 
of nasal tumors observed in naphthalene-exposed rats.  Figure 10 replots models D and D* for 
each tumor type as corresponding functions of additional (i.e., increased) mutagenic risk, M–1.  
The ratio of slopes for models D and D* as M→1 thus represents, for each tumor type, a 
plausible lower bound on the magnitude of corresponding MOA-related uncertainty associated 
with any low-dose extrapolation that is premised on a genotoxic MOA, for cancer risk posed by 
naphthalene based on the modeled bioassay data.  These slope ratios are 31 and 10.7 for NREA 
and NRON, respectively.  It is emphasized that these factors address MOA-related uncertainty 
only, and do not address or in any way account for likely additional conservatism associated with 
linear, GMOA-based extrapolation of low-dose risk from the NTP rat tumor data without first 
adjusting for the pharmacokinetic relationship, in rodents and in humans, between (applied)  
 
     
Figure 10.  MOA-specific MVK models D (bold green curve) and D* (light green curve) of NREA and 
NRON tumor incidence in NTP bioassay rats, replotted from Figure 9 as a function of net relative 
mutagenic risk, (M–1).  In each plot, the bold black (lowermost) curve shows the baseline MVK model fit 
to the indicated control tumor incidence rate, to which baseline all of the models considered collapse at 
zero dose; the bold blue (uppermost), red and green curves show models G, C and D, respectively; and 
the light green curve shows model D*.  The jagged light black step function is the approximate survival 
function based on corresponding adjusted empirical bioassay survival data. 
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naphthalene concentration and biologically effective dose (e.g., of 1,2- and/or 1,4-
naphthoqhinone adducts with DNA in putative stem cells) in susceptible target tissues.  It is clear 
(e.g., from Figure 6) that for naphthalene this relationship is quite nonlinear, and likely is tightly 
related to corresponding target-cell-specific levels of glutathione depletion.  Pharmacokinetic 
uncertainty for these tumor endpoints should be addressed separately by applying PBPK models 
after validation using relevant (including required new, tissue-specific) experimental data.  
However, the MVK-bounding approach illustrated above supports the application of MOA-
specific uncertainty factors of about 1/30 and 1/10 to linearly extrapolated risk estimates from 
NTP rat bioassay data on NREA and NRON tumor endpoints, respectively, if such 
extrapolations (e.g., by default) presume a genotoxic MOA.  Note that the MVK approach used 
did not involve any low-dose extrapolation model of tumor risk as a function of administered 
dose (i.e., bioassay concentration of naphthalene). 
 Within the range of plausible values of m0 considered, different corresponding values of 
N could be used to obtain the same MVK model fits, consistent with the Heidenreich et al. 
(1997) identifiability constraint.  However, it was found that such small changes within this 
range affected neither fundamental MVK model behaviors nor their quantitative implications in a 
major way, nor corresponding conclusions reached.  The models were, however, quite sensitive 
to values used for parameters n, K and b0, and conclusions reached must be interpreted with this 
sensitivity in mind, particularly insofar as improved estimates of these parameters could be 
obtained experimentally, using methods similar to those used to better understand the role of cell 
kinetics in formaldehyde-induced nasal tumors in rats (Monticello et al., 1996).  The proposed 
approach could be extended to address multiple (>2) groups of bioassay data, e.g., using formal 
maximum likelihood methods. 
 
Discussion 
 Bioassay data, supplemental toxicokinetic data, and related physiologically based 
pharmacokinetic and 2-stage stochastic carcinogenesis modeling results all clearly indicate that 
naphthalene is a DMOA carcinogen.  Although genotoxicity associated with reactive 
naphthalene metabolites may theoretically contribute to increased risk at all doses, the USEPA 
Guidelines (2005) imply that for such a chemical, judgment be used to compare and assess 
approaches to low-level risk extrapolation  based solely on models that posit either a genotoxic 
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or a cytotoxic MOA, such as models G and C considered above.  A DMOA approach (i.e., an 
approach involving a nongenotoxic MOA) is evidently allowed only when evidence is sufficient 
to fully parameterize a biologically based model that reliably extrapolates risk to low levels of 
concern.  The Guidelines thus hinder consideration of MOA uncertainty when data are 
insufficient to parameterize such a model, but otherwise clearly support a DMOA.  In the case of 
naphthalene-induced rat nasal tumors, it was shown that a bounding factor approach—similar to 
that used in reference dose procedures for classic toxicity endpoints—can address MOA 
uncertainty in a way that avoids explicit modeling of low-dose risk as a function of administered 
or internal dose.  Even though data are not yet sufficient to fully validate a “nonlinear” 
toxicokinetic model for naphthalene, implications of DMOA uncertainty on low-dose risk could 
be bounded with reasonable confidence because the target tumor types involved happen to be 
extremely rare.  Plausibility bounds on rat-tumor-type specific DMOA-related uncertainty were 
obtained using a 2-stage model adapted to reflect the empirical link between genotoxic and 
cytotoxic effects of the most potent identified genotoxic naphthalene metabolites, 1,2- and 1,4-
naphthoquinone.  Resulting bounds each provided the basis for a corresponding “uncertainty” 
factor between 1/30 and 1/10 appropriate to apply to estimates of naphthalene risk obtained by 
linear extrapolation under a default genotoxic MOA assumption.  This procedure merits 
exploration as a way to address MOA uncertainty for other DMOA carcinogens. 
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APPENDIX 
Excerpts from the USEPA (2005) Guidelines for Carcinogen Risk Assessment 
 
3.2 ANALYSES IN THE RANGE OF OBSERVATION.  
3.2.2. Toxicodynamic (“Biologically Based”) Modeling.  
 … It is possible for different models to provide equivalent fits to the observed data but to 
diverge substantially in their projections at lower doses. When model parameters are estimated 
from tumor incidence data, it is often the case that different combinations of parameter estimates 
can yield similar results in the observed range. For this reason, critical parameters (e.g., mutation 
rates and cell birth and death rates) are estimated from laboratory studies and not by curve-fitting 
to tumor incidence data (Portier, 1987). This approach reduces model uncertainty (see Section 
3.6) and ensures that the model does not give answers that are biologically unrealistic. … 
Toxicodynamic modeling can provide insight into the relationship between tumors and key 
precursor events. For example, a model that includes cell proliferation can be used to explore the 
extent to which small increases in the cell proliferation rate can lead to large lifetime tumor 
incidences (Gaylor and Zheng, 1996). [p. 3-14] 
 
3.3 EXTRAPOLATION TO LOWER DOSES. 
3.3.1. Choosing an Extrapolation Approach 
The approach for extrapolation below the observed data considers the understanding of 
the agent's mode of action at each tumor site (see Section 2.4). Mode of action information can 
suggest the likely shape of the dose-response curve at lower doses. The extent of inter-individual 
variation is also considered, with greater variation spreading the response over a wider range of 
doses.  
Linear extrapolation should be used when there are MOA data to indicate that the dose-
response curve is expected to have a linear component below the POD. Agents that are generally 
considered to be linear in this region include: 
 
• agents that are DNA-reactive and have direct mutagenic activity, … 
 
When the weight of evidence evaluation of all available data are insufficient to establish 
the mode of action for a tumor site and when scientifically plausible based on the available 
data, linear extrapolation is used as a default approach, because linear extrapolation generally is 
considered to be a health-protective approach. Nonlinear approaches generally should not be 
used in cases where the mode of action has not been ascertained. Where alternative approaches 
with significant biological support are available for the same tumor response and no scientific 
consensus favors a single approach, an assessment may present results based on more than one 
approach  
A nonlinear approach should be selected when there are sufficient data to ascertain the 
mode of action and conclude that it is not linear at low doses and the agent does not 
demonstrate mutagenic or other activity consistent with linearity at low doses. Special attention 
is important when the data support a nonlinear mode of action but there is also a suggestion of 
mutagenicity. Depending on the strength of the suggestion of mutagenicity, the assessment may 
justify a conclusion that mutagenicity is not operative at low doses and focus on a nonlinear 
approach, or alternatively, the assessment may use both linear and nonlinear approaches.  
Both linear and nonlinear approaches may be used when there are multiple modes of 
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action. If there are multiple tumor sites, one with a linear and another with a nonlinear mode of 
action, then the corresponding approach is used at each site. If there are multiple modes of 
action at a single tumor site, one linear and another nonlinear, then both approaches are 
used to decouple and consider the respective contributions of each mode of action in 
different dose ranges. For example, an agent can act predominantly through cytotoxicity at 
high doses and through mutagenicity at lower doses where cytotoxicity does not occur. 
Modeling to a low response level can be useful for estimating the response at doses where 
the high-dose mode of action would be less important. [pp, 3-21 – 3-22, emphasis added] 
 
3.3.2. Extrapolation Using a Toxicodynamic Model  
The preferred approach is to develop a toxicodynamic model of the agent’s mode of 
action and use that model for extrapolation to lower doses (see Section 3.2.2). The extent of 
extrapolation is governed by an analysis of model uncertainty, where alternative models that fit 
similarly in the observed range can diverge below that range (see Section 3.6). Substantial 
divergence is likely when model parameters are estimated from tumor incidence data, so that 
different combinations of parameter estimates yield similar fits in the observed range but have 
different implications at lower doses. An analysis of model uncertainty can be used to determine 
the range where extrapolation using the toxicodynamic model is supported and where further 
extrapolation would be based on either a linear or a nonlinear default, as appropriate (see 
Sections 3.3.3, 3.3.4). [p. 3-22] 
 
3.3.3. Extrapolation Using a Low-dose, Linear Model  
Linear extrapolation should be used in two distinct circumstances: (1) when there are data 
to indicate that the dose-response curve has a linear component below the POD, or (2) as a 
default for a tumor site where the mode of action is not established (see Section 3.3.1). For linear 
extrapolation, a line should be drawn from the POD to the origin, corrected for background. [p. 
3-23] 
 
3.3.4. Nonlinear Extrapolation to Lower Doses  
A nonlinear extrapolation method can be used for cases with sufficient data to 
ascertain the mode of action and to conclude that it is not linear at low doses but with not 
enough data to support a toxicodynamic model that may be either nonlinear or linear at low 
doses. Nonlinear extrapolation having a significant biological support may be presented in 
addition to a linear approach when the available data and a weight of evidence evaluation 
support a nonlinear approach, but the data are not strong enough to ascertain the mode of 
action applying the Agency’s mode of action framework. If the mode of action and other 
information can support chemical-specific modeling at low doses, it is preferable to default 
procedures.  
For cases where the tumors arise through a nonlinear mode of action, an oral reference 
dose or an inhalation reference concentration, or both, should be developed in accordance with 
EPA’s established practice for developing such values [involving application of “uncertainty 
factors” to Benchmark , no-observed-effect or lowest-observed-effect dose levels], taking into 
consideration the factors summarized in the characterization of the POD (see Section 3.2.5). 
[p. 3-23 – 3-24] 
 
3.3.5. Comparing and Combining Multiple Extrapolations  
When multiple estimates can be developed, all datasets should be considered and a 
judgment made about how best to represent the human cancer risk. [p. 3-24] 
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